Catalent (NYSE:CTLT) has tumbled 6.42% during the past week and has dropped 25.17% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 5.29%. Catalent (NYSE:CTLT) has underperformed the index by 25.85% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Catalent (NYSE:CTLT): The stock opened at $22.15 on Friday but the bulls could not build on the opening and the stock topped out at $22.20 for the day. The stock traded down to $21.30 during the day, due to lack of any buying support eventually closed down at $21.44 with a loss of -3.29% for the day. The stock had closed at $22.17 on the previous day. The total traded volume was 3,506,528 shares.
The company shares have dropped -30.37% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $34.42 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $25.87 and the 200 Day Moving Average price is recorded at $25.67.
On the companys insider trading activities, Walsh Matthew M, officer (See Remarks) of Catalent, Inc., unloaded 21,197 shares at an average price of $28.85 on May 27, 2016. The total amount of the transaction was worth $611,533, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. William Blair downgrades their rating on the shares of Catalent (NYSE:CTLT). The current rating of the shares is Market Perform. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on May 5, 2016. Currently the company Insiders own 0.98% of Catalent shares according to the proxy statements. Institutional Investors own 99.72% of Catalent shares.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.